EUVIMEDEUVIMED entdecken
Crossref

Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection

Yun-Chu Chen iD, Yu-Ping Chang iD, Jenna Bedrava iD, Laurel Jackson, Ji-Yuh Lee, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang iD, Yu-Lueng Shih iD, Cheng-Yuan Peng iD, Fu-Jen Lee iD und 9 weitere

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Yun-Chu Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatitis C, Chronic, Biomarkers, Membrane Proteins. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Abbott Laboratorie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical utility of serum Golgi protein 73 (GP73) for evaluating hepatic fibrosis in hepatitis C virus (HCV) infection remains to be determined. We retrospectively enrolled 978 patients with serum GP73, aspartate‐to‐platelet ratio index (APRI), and Fibrosis‐4 (FIB‐4) measurements. Hepatic fibrosis was staged using vibration‐controlled transient elastography (VCTE) with cutoff values of ≤ 7.0, 7.1–9.4, 9.5–12.4, and ≥ 12.5 kPa corresponding to F0–F1, F2, F3, and F4. Distributions of GP73, APRI, and FIB‐4 levels across fibrosis stages were compared using Kruskal–Wallis tests. Areas under the receiver operating characteristic curves (AUROCs) were calculated and compared using DeLong tests, and optimal GP73 cutoff values were determined by maximal Youden indices. Multivariable linear regression was performed for factors associated with GP73 levels. Median GP73, APRI, and FIB‐4 levels increased with advancing fibrosis stage ( p < 0.001). Serum GP73 showed superior performance to APRI in discriminating ≥ F2 (AUROC 0.86 vs. 0.79, p < 0.001), ≥ F3 (0.88 vs. 0.81, p < 0.001), and F4 (0.90 vs. 0.84, p = 0.002). GP73 showed better performance than FIB‐4 for ≥ F2 (0.86 vs. 0.82, p = 0.005) and comparable performance for ≥ F3 (0.88 vs. 0.87, p = 0.63) and F4 (0.90 vs. 0.89, p = 0.72). Optimal GP73 cutoff values were 122, 159, and 174 ng/mL for ≥ F2, ≥ F3, and F4. Regression analysis demonstrated a significant association between fibrosis stage and GP73 levels. In conclusion, serum GP73 is a reliable and accurate noninvasive biomarker for staging hepatic fibrosis for HCV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisHepatitis C, ChronicBiomarkersMembrane ProteinsHumansMaleRetrospective StudiesFemaleMiddle AgedElasticity Imaging TechniquesROC CurveAdultAgedSeverity of Illness Index

Stichwörter der Autor:innen

golgi protein 73hepatic fibrosishepatitis C virusliver stiffness measurementvibration‐controlled transient elastography

Substanzen

BiomarkersMembrane ProteinsGOLM1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Clinical Statistics, Core Diagnostics, Abbott Laboratories, USA.
  • Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine,College of Medicine, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Yun-Chu Chen, Yu-Ping Chang, Jenna Bedrava, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Fu-Jen Lee, Tung-Hung Su, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao, Claire Chen, Chen-Hua Liu

Förderung

  • Abbott Laboratorie

Zitieren

APA

Chen, Y. C., Chang, Y. P., Bedrava, J., Jackson, L., Lee, J. Y., Chen, C. Y., Kao, W. Y., Lin, C. L., Yang, S. S., Shih, Y. L., Peng, C. Y., Lee, F. J., Tsai, M. C., Huang, S. C., Su, T. H., Tseng, T. C., Liu, C. J., Chen, P. J., Kao, J. H., …, & Liu, C. H. (2026). Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.71183

Vancouver

Chen YC, Chang YP, Bedrava J, Jackson L, Lee JY, Chen CY, et al. Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection. Journal of Medical Virology. 2026. doi:10.1002/jmv.71183

BibTeX
@article{Chen2026,
  author = {Chen, Yun-Chu and Chang, Yu-Ping and Bedrava, Jenna and Jackson, Laurel and Lee, Ji-Yuh and Chen, Chi-Yi and Kao, Wei-Yu and Lin, Chih-Lin and Yang, Sheng-Shun and Shih, Yu-Lueng and Peng, Cheng-Yuan and Lee, Fu-Jen and Tsai, Ming-Chang and Huang, Shang-Chin and Su, Tung-Hung and Tseng, Tai-Chung and Liu, Chun-Jen and Chen, Pei-Jer and Kao, Jia-Horng and Chen, Claire and Liu, Chen-Hua},
  title = {Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71183}
}
Kostenlos starten →